Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1 by McDonald, Merry-Lynn Noelle et al.
Body mass index change in gastrointestinal cancer and
chronic obstructive pulmonary disease is associated
with Dedicator of Cytokinesis 1
Merry-Lynn Noelle McDonald1*, Sungho Won2, Manuel Mattheisen3, Peter J. Castaldi1,4, Michael H. Cho1,5, Erica
Rutten6, Megan Hardin1,5, Wai-Ki Yip7, Stephen I. Rennard8, David A. Lomas9, Emiel F.M. Wouters6,10, Alvar Agusti11,
Richard Casaburi12, Christoph P. Lange7, George O’Connor13,14, Craig P. Hersh1,5 & Edwin K. Silverman1,5
1Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2Department of Public Health Science, Seoul National
University, Seoul, South Korea; 3Department of Biomedicine and Centre for integrative Sequencing (iSEQ), Aarhus University, Aarhus, Denmark; 4Division of Primary Care and
Internal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 5Division of Pulmonary and Critical Care Medicine, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA, USA; 6CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, The Netherlands; 7Department of Biostatistics, Harvard
School of Public Health, Boston, MA, USA; 8Department of Medicine, Nebraska Medical Center, Omaha, Nebraska, USA; 9UCL Respiratory, Division of Medicine, University
College London, London, UK; 10Department of Respiratory Medicine, Maastricht University Medical Center Maastricht, Maastricht, The Netherlands; 11Thorax Institute,
Hospital Clinic-IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain; 12Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute, Harbor-UCLA
Medical Center, Torrance, CA, USA; 13The National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, MA, USA; 14Section of Pulmonary, Allergy, and
Critical Care Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Abstract
Background There have been a number of candidate gene association studies of cancer cachexia-related traits, but no
genome-wide association study (GWAS) has been published to date. Cachexia presents in patients with a number of
complex traits, including both cancer and COPD. The objective of the current investigation was to search for a shared
genetic aetiology for change in body mass index (ΔBMI) among cancer and COPD by using GWAS data in the Framingham
Heart Study.
Methods A linear mixed effects model accounting for age, sex, and change in smoking status was used to calculate ΔBMI in
participants over 40 years of age with three consecutive BMI time points (n = 4162). Four GWAS of ΔBMI using generalized
estimating equations were performed among 1085 participants with a cancer diagnosis, 204 with gastrointestinal (GI) cancer,
112 with lung cancer, and 237 with COPD to test for association with 418 365 single-nucleotide polymorphisms (SNPs).
Results Two SNPs reached a level of genome-wide signiﬁcance (P< 5×108) with ΔBMI: (i) rs41526344 within the CNTN4 gene,
among COPD cases (β =0.13, P=4.3 × 108); and (ii) rs4751240 in the gene Dedicator of Cytokinesis 1 (DOCK1) among GI cancer
cases (β = 0.10, P= 1.9 ×108). The DOCK1 SNP association replicated in the ΔBMI GWAS among COPD cases (βmeta-analyis = 0.10,
Pmeta-analyis = 9.3 × 10
10). The DOCK1 gene codes for the dedicator of cytokinesis 1 protein, which has a role in myoblast fusion.
Conclusions In sum, one statistically signiﬁcant common variant in the DOCK1 gene was associated with ΔBMI in GI cancer
and COPD cases providing support for at least partially shared aetiology of ΔBMI in complex diseases.
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Introduction
Despite the success of genome-wide association studies
(GWASes) at identifying thousands of associations with
hundreds of complex diseases and traits,1 there has been
no published GWAS investigating a cancer cachexia-related
trait. Although there have been a number of published
candidate-gene association studies investigating cancer
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cachexia-related traits (reviewed in Refs2,3), candidate-
gene association studies are limited to known biology
and do not take advantage of the agnostic, hypothesis-
free approach of genome scans. Thus, the cancer cachexia
community would beneﬁt from GWASes in order to dis-
cover new genes and pathways involved in the aetiology
of cachexia.
Body mass index (BMI) is a highly heritable cross-sectional
measure that is frequently employed to monitor changes in
body composition in epidemiological studies. Over 100
genetic loci have been associated with BMI.4,5 Changes in
BMI (ΔBMI) have also been shown to be heritable with
estimates ranging from 0.14 to 0.86.6,7 At one end of the
BMI spectrum, obesity is a known risk factor for a number
of complex diseases. At the other end of the spectrum, pa-
tients who lose weight are also at increased risk of mortality,
which is the impetus for investigating muscle wasting and ca-
chexia.8 Cachexia can be characterized in part as a rapid
change in weight, including loss of fat-free muscle, as part
of the pathology of an illness.8 Cachexia is often thought of
with respect to cancer; however, it occurs in patients suffer-
ing from many chronic, complex diseases, including chronic
obstructive pulmonary disease (COPD), congestive heart fail-
ure, AIDS, and cystic ﬁbrosis, among others.8,9 In fact, the num-
ber of COPD patients with cachexia was recently estimated to
be 1.4 times higher than the number of cancer patientswith ca-
chexia.10 Regardless of the primary complex disease diagnosis,
cachexia is associated with poor prognosis and an increased
burden on the healthcare system.8,11
In the current report, we begin to ﬁll the gap in reported
GWASes investigating cachexia-related traits. We analysed
genetic data available via public access (dbGaP) from the
Framingham Heart Study (FHS).12 In the current manuscript,
we integrated data from GWAS of ΔBMI in cancer and COPD
cases to search for overlapping genetic variants.
Materials and methods
Study population
Ethics approval was obtained for the proposed analyses from
the Brigham and Women’s Hospital Institutional Review
Board and has been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki and
its later amendments. Phenotype and genotype data from
FHS were used in the analyses. The FHS is a longitudinal
population-based study of individuals from Framingham,
MA.12 FHS genotype and phenotype data were downloaded
through authorized accession obtained from National Insti-
tutes of Health Data Access Committee of dbGaP
phs000007.v16.p6. Genotype data from the Affymetrix 500 k
mapping array plus the Affymetrix 50 k supplemental array
(phs000342.v4.p6) were used in the analyses.
Generating change in body mass index phenotype
in cancer and chronic obstructive pulmonary
disease cases
Figure 1A depicts a ﬂowchart illustrating the number of
subjects included in the analyses with genotype, ΔBMI,
and additional phenotype (cancer and/or COPD diagnoses).
Using the FHS data, ΔBMI was calculated by using the last
three consecutive time points (~2–4 years apart) for indi-
viduals over 40 years of age who participated in the Orig-
inal and Offspring Cohorts by using a random slope and
intercept linear mixed effects model accounting for age,
sex, and change in smoking status as ﬁxed effects. COPD
diagnosis was generated by using spirometry13 reported
at visits 16, 17, and 19 in the FHS Original Cohort and
Figure 1 (A) Flowchart of number of subjects included in analyses with genotype, change in body mass index and additional phenotype data. (B) Venn
diagram representing overlap between all subjects with change in body mass index, cancer, and chronic obstructive pulmonary disease diagnoses.
Counts are based on the number of participants with genotype data and change in body mass index variable.
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visits 5, 6, 7, and 8 in the FHS Offspring Cohort. An indi-
vidual was coded as having COPD if they had at least
two moderately obstructed (or worse) spirometry tests
(FEV1< 80% and FEV1/FVC< 0.7) that did not improve at
a later visit (n = 344). An individual was coded as having
any cancer if they reported a cancer diagnosis as coded
with SEER ICD-O topography (TOPO) codes at any time
during the study (n = 1085). Please see Table S1 for speciﬁc
details on the TOPO codes used. Overall, 4162 participants
had information to calculate ΔBMI and genotype data. Of
these, 1085 had a cancer diagnosis, 344 had COPD based
on lung function, 204 had a GI cancer diagnosis, and 112
had a lung cancer diagnosis. A total of 237 COPD cases
did not also have a concurrent cancer diagnosis based
on TOPO codes.
Genome-wide association studies of change in
body mass index
Genotyping quality control procedures were used to ensure
high-quality data for association testing. The Affymetrix
500 k and 50 k data were cleaned separately and then com-
bined prior to association testing. Brieﬂy, DNA samples were
excluded if missing more than 3% of genotypes, if reported
familial relationships did not agree with those estimated from
the genotypes, exhibited excess heterozygosity or homozy-
gosity, or were outliers by using principal components analy-
sis to detect population substructure. Single-nucleotide
polymorphisms (SNPs) that failed genotyping in more than
5% of the samples or with Hardy–Weinberg equilibrium P-
values less than 1 × 107 were removed. SNP analyses were
restricted to autosomal variants with minor allele frequencies
greater than 5%. A total of 4 GWAS (within COPD, all cancer,
lung cancer, and GI cancer subjects) were performed by
using generalized estimating equations accounting for fam-
ily structure in FHS to test for association between 418 365
SNPs and ΔBMI by using the R library GWAF.14 All GWAS
ﬁndings were further adjusted by using genomic control
to control for population substructure.15 Meta-analyses were
performed between independent samples from FHS cancer
cases and FHS COPD cases without cancer, assuming a ﬁxed ef-
fects model by using metal software.16 Meta-analysis results
with Pheterozygosity< 0.1 were excluded. Regional association
plots were generated by using LocusZoom.17 HaploReg v4.1
was used to assess the relationship between signiﬁcant GWAS
SNPs and epigenomic annotations in cell types from the
Roadmap Epigenomics and ENCODE projects.18 The results
with P< 5 × 108 were considered statistically/genome-wide
signiﬁcant (GWS) accounting both for the number of variants
tested and the linkage disequilibrium (LD) structure of the
genome.19,20
Results
Cancer and chronic obstructive pulmonary disease
population characteristics
Only subjects over the age of 40 with at least 3 consecu-
tive BMI measurements in FHS were considered for the
analyses. There was some overlap in cancer and COPD di-
agnoses in the population (Figure 1B). Among FHS partici-
pants who had a COPD diagnosis, 107 (31.1%) also
reported a cancer diagnosis of which 18 (5.2%) had GI can-
cer and 26 (7.6%) had lung cancer. In the current genetic
analysis, COPD cases with a cancer diagnosis were excluded
from the COPD ΔBMI GWAS to create an independent case
population for meta-analyses.
Table 1 summarizes the characteristics of cancer and
COPD cases from the FHS included in the analyses. A total
of 4162 FHS participants over the age of 40 at baseline
BMI measurement had three consecutive time points avail-
able to generate ΔBMI. Among these FHS participants, 237
had COPD based on spirometry without concurrent re-
ported cancer diagnoses, 1085 had some type of cancer
(except non-melanoma skin cancer), 204 had GI cancer,
and 112 had lung cancer (Figure 1). The percentage of
men was comparable between the COPD cases and the
Table 1 Characteristics of cancer and chronic obstructive pulmonary disease cases in Framingham Heart Study used in analyses
Framingham Heart Study (FHS)
All Any cancer COPDa GI cancer Lung cancer
n 4162 1085 237 204 112
Sex (% male) 45.2 51.8 45.6 52 57.1
Median initial BMI (IQR) 26.8 (6.0) 27 (5.7) 26.4 (6.1) 26.7 (5.6) 25.8 (4.9)
Median initial age (IQR) 62 (19 ) 66 (17) 61 (15) 69 (19) 66 (15.2)
Median follow-up time (IQR) 9 (4) 8 (4) 8 (6) 7 (5) 7 (4)
Median ΔBMI (IQR) 0.01 (0.2) 0.01(0.1) 0.03 (0.2) 0.02 (0.1) 0.008 (0.1)
ΔBMI, change in body mass index; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; IQR, interquartile range.
aChronic obstructive pulmonary disease cases without any cancer. Chronic obstructive pulmonary disease in FHS was coded by
using lung function testing. Initial age and BMI in FHS are based the ﬁrst of three consecutive time points an individual partici-
pated in FHS.
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total subset with ΔBMI, whereas there were more men
with a cancer diagnosis in the FHS data than total subset
with ΔBMI (Table 1). The lung cancer population had the
highest percentage of men (57.1%). Baseline BMI was com-
parable between the total FHS with ΔBMI, COPD, and can-
cer subsets. The FHS participants with a cancer diagnosis
were older (median: 66 years) than those with COPD with-
out cancer (median: 61 years) and the collective FHS popu-
lation with ΔBMI (median: 62 years). The GI cancer case
subset had the oldest median baseline age of 69 years
(Table 1). The follow-up time was comparable among the
COPD, cancer, and total populations with ΔBMI (follow-up
time range: 7–9 years). Overall, most participants’ BMI in-
creased slightly (median ΔBMI: 0.01) during the interval
used to evaluate BMI. On average, the COPD population’s
BMI increased the most (median ΔBMI: 0.03), and the GI
cancer population was the only population that lost BMI
overall (median ΔBMI: 0.02).
Genome-wide association studies of change in
body mass index in cancer and chronic obstructive
pulmonary disease cases
The quantile–quantile and Manhattan plots summarizing
the results from the individual ΔBMI GWASes among can-
cer and COPD cases are presented in Figures S1–S4. All
SNP results with suggestive associations (P< 5 × 105) are
presented in Tables S2–S5. No SNP reached a level of
GWS (P< 5 × 108) in the GWAS of ΔBMI among all cancer
cases (Figure S1). However, two SNPs achieved GWS with
ΔBMI separately among COPD or GI cancer cases. More
speciﬁcally, rs41526344, within the CNTN4 gene, was signif-
icantly associated with ΔBMI among COPD cases (β = 0.13,
P = 4.3 × 108). CNTN4 codes for contactin 4, a neuronal
network axon-associated cell adhesion molecule implicated
in the genetics of neuropsychiatric disorders.21 Further,
rs4751240 was signiﬁcantly associated with ΔBMI among
GI cancer cases (β = 0.10, P = 1.9 × 108) and is located
within the Dedicator of Cytokinesis 1 (DOCK1) gene, which
codes for the dedicator of cytokinesis 1 protein and has a
role in myoblast fusion.22 The DOCK1 SNP, rs4751240, has
a minor allele frequency of 7% in the GI cancer population,
and under Hardy–Weinberg equilibrium, we would expect
that 0.5% of the population would be homozygous for
the variant and 13% would be heterozygous. For the
rs41526344 SNP within the CNTN4 gene, we would expect
0.8% of the population to be homozygous and 14.6% to
be heterozygous based on the minor allele frequency in
the COPD population. The observed genotype frequencies
did not differ signiﬁcantly from those predicted based on
the Hardy–Weinberg equilibrium test for these variants or
any variant reported in this study.
Top single-nucleotide polymorphisms associated
with change in body mass index among both
cancer and chronic obstructive pulmonary disease
cases
To test the hypothesis that shared variants are associated
with ΔBMI among cancer and COPD cases, meta-analyses of
the ΔBMI GWASs between cancer and COPD cases were per-
formed. For example, separate meta-analyses were run be-
tween the ΔBMI GWASes from GI cancer and COPD cases,
between the ΔBMI GWASes from lung cancer cases and
COPD cases, and so forth. All meta-analysis results with sug-
gestive associations (P< 5 × 105) are presented in Tables
S8–S10. No variant achieved a level of GWS in the meta-
analysis between all cancer cases and COPD cases. The top
SNP rs188981 (βmeta-analysis: 0.025, Pmeta-analysis = 6.6 × 106)
is located in an intergenic region on chromosome 3 between
the genes SUCNR1 and MBLN1 (Figure 2A and Table S6). The
GWS association observed among the DOCK1 SNP,
rs4751240, and ΔBMI in GI cancer was replicated in the COPD
ΔBMI GWAS (βCOPD: 0.08, PCOPD = 0.014, βmeta-analysis: 0.1,
Pmeta-analysis = 9.3 × 10
10; Table S7). This β accounts for a
mean increase of 0.1 kg/m2 BMI per year in GI cancer cases
and of 0.08 kg/m2 BMI per year in COPD cases after taking
age, sex, and change in smoking status into account for each
copy of the rs4751240 minor allele (Figure 3). The regional
association plot (Figure 2B) demonstrates that the genotyped
rs4751240 SNP is intronic within the coding region of DOCK1
and is not in LD with other genotyped variants. When
HaploReg was used to examine LD of variants with
rs4751240 by using the 1000 Genomes Project haplotypes,
only one other variant in the region is in high LD with this
SNP (Table S8). The investigation using HaploReg also re-
vealed that rs4751240 alters a motif23 corresponding to the
tumour suppressor Nkx2-8.22,23 We also identiﬁed an associ-
ation in the meta-analysis of ΔBMI between lung cancer and
COPD cases near the FAM73B gene (rs7042889, βmeta-analysis:
0.14, Pmeta-analysis = 1.4 × 107; Table S10). The HaploReg in-
vestigation revealed that rs7042889 is in high LD with eight
SNPs that alter regulatory motifs, including rs7873667 which
alters a number of motifs including several forkhead box
(Fox) motifs (Table S10).
Discussion
In summary, we report ﬁndings from the ﬁrst GWAS of a
cachexia-related trait, ΔBMI, among cancer and COPD cases.
We found one SNP, rs41526344, signiﬁcantly associated with
ΔBMI among COPD cases in the CNTN4 gene but were unable
to replicate it. The DOCK1 SNP rs4751240 was signiﬁcantly as-
sociated with ΔBMI among GI cancer cases and replicated
among COPD cases. We also identiﬁed a nearly signiﬁcant
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association with rs7042889 in the meta-analysis of ΔBMI be-
tween lung cancer and COPD cases near the FAM73B gene.
The rs4751240 SNP in the DOCK1 gene achieved a level of
GWS (P< 5 × 108) in the analysis of ΔBMI among GI cancer
cases and replicated nominally in the analyses among COPD
cases. DOCK1 is a guanine nucleotide exchange factor,
catalysing the exchange of GDP to GTP to activate Rho pro-
teins.24 In mouse models, knockout of DOCK1 is embryonic le-
thal with a dramatic reduction of skeletal muscle tissues
attributed to a deﬁciency in myoblast fusion.22 Myoblast fu-
sion is also critical for satellite cell-mediated muscle regener-
ation in adults.25 As cachexia can be the result of both
Figure 2 Regional association plots of the top regions identiﬁed in the meta-analysis between cancer and chronic obstructive pulmonary disease
cases: (A) The region on chromosome 3 where the top variant from the meta-analysis investigating change in body mass index among any cancer
and chronic obstructive pulmonary disease cases rs188981 (β: 0.025, P = 6.0 × 106) is located in an intergenic region between the genes SUCNR1
and MBLN1. (B) Displays the DOCK1 region on chromosome 9, where the top variant rs4751240 (β = 0.1, P = 9.3 × 1010) in the meta-analysis between
investigating change in body mass index among gastrointestinal cancer and chronic obstructive pulmonary disease cases is located.
Figure 3 Boxplot of change in body mass index stratiﬁed by DOCK1 SNP rs4751240 genotype between (A) gastrointestinal cancer cases and (B) and
chronic obstructive pulmonary disease cases.
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increased muscle breakdown and decreased muscle produc-
tion, genetic variation in DOCK1 may inﬂuence muscle regen-
eration. The DOCK1 SNP, rs4751240, is an intronic variant.
SNPs in non-coding regions of the genome may directly alter
or may be in LD with genetic variants that alter regulatory re-
gions such as transcription factor or enhancer binding sites
and in turn have an effect on gene expression and protein
abundance.26 The rs4751240 SNP is within a motif for the tu-
mour suppressor Nkx2-8, whose mechanism of tumour sup-
pression is by up-regulating FOXO3a protein encoded by the
FOXO3 gene.27 The Fox class O (FoxO) transcription factor
family members FOXO1 and FOXO3 are well known to play a
role in energy metabolism, protein breakdown, regulation of
muscle mass, and adaptation to exercise.28 All FoxOs are acti-
vated in response to insulin stimulation and/or oxidative
stress by phosphorylation at three evolutionarily conserved
sites.28 Interestingly, the top SNP associated with ΔBMI in
the meta-analysis of lung cancer and COPD cases is in high
LD with rs7873667 (Table S10) that disrupts several Fox tran-
scription factors, including FoxO. In a recent mega-GWAS,
rs9400239 in FOXO3 was signiﬁcantly associated with cross-
sectional BMI (β = 0.0019, P = 1.61 × 108) in individuals of
European ancestry, further supporting the role of this path-
way in determining BMI.4
The topﬁnding in themeta-analysisofΔBMIbetweenall can-
cer and COPD cases is intergenic to SUCNR1 and MBLN1.
SUCRN1 codes for the succinate receptor 1 gene, which is a G-
protein coupled receptor for succinate, an intermediate of the
citric acid cycle.29 MBLN1 codes for the muscleblind-like splic-
ing regulator 1, which plays a role in myotonic dystrophy and
knockout of the gene in the mouse leads to muscle abnormali-
ties and cataracts.30 This result, however, fails to achieve a level
of genome-wide signiﬁcance. The power of the analysismay be
limited both by the sample size and heterogeneity ofΔBMI tra-
jectories among different types of cancer. The analyses that
were performed among different cancer types further reduced
the sample size butmayhave increased thehomogeneity of the
ΔBMI trajectory, thereby increasing thepower todetect the sig-
niﬁcant association in the GI cancer group.
We identiﬁed one variant, rs41526344, signiﬁcantly associ-
ated with ΔBMI among COPD cases in the CNTN4 gene, cod-
ing for contactin-4. Contactins are a family of neural
immunoglobulin cell adhesion molecules (IgCAMs) with six
N-terminal immunoglobulin repeats followed by four ﬁbro-
nectin type III repeats. The prototypical contactin is
contactin-1 with shared amino acid identity ranging from 33
to 52% identity with contactin-4 depending on the domain.21
Genetic variations in CNTN4, CNTN5, and CNTN6 have been
associated with autism spectrum disorders.31 Increased signal
transduction via the mTOR signal transduction pathway is
one mechanism common to many autism spectrum disorder
genes including contactins.31 Interestingly, decreased mTOR
signalling is observed during fasting and disease as muscle
growth and atrophy depends on the mTOR pathway.32
Further, mutations in CNTN1 cause a familial form of the le-
thal congenital myopathy, a disease whose hallmark is low
muscle tone.33 In the current study, we identiﬁed a signiﬁcant
association with a CNTN4 SNP with ΔBMI among COPD cases;
however, we were not able to replicate the ﬁndings among
cancer cases.
There have been a number of candidate gene association
studies investigating the genetics of cancer cachexia-related
traits such as low BMI, low FFMI, weight loss, and muscle
strength, but no GWAS has been reported to our knowledge.
Systematic reviews of the genetics of cancer cachexia
highlighted genes involved in inﬂammatory response regula-
tion, homeostasis, pathways directing muscle and fat metab-
olism, and appetite regulation.2,3 Among COPD cases, muscle
quadricep muscle strength and low FFMI candidate gene
studies have reported associations with the Angiotensin
Converting Enzyme gene,34 Bradykinin Receptor gene,35
IL1β,36 IL6,36 TNFα,36 and vitamin D receptor.37 Wan and col-
leagues from our research group38 reported GWASes ﬁndings
investigating two continuous outcomes, BMI and FFMI, in
COPD cases. They found several SNPs tagging the fat-mass
and obesity (FTO) gene signiﬁcantly associated (meta-analy-
sis: P< 5 × 107) with reduced BMI and FFMI in COPD cases.
Single-nucleotide polymorphisms in the FTO gene have been
repeatedly associated with BMI39–44 and diabetes.45 It is in-
teresting to note that we did not ﬁnd statistically signiﬁcant
associations with any known cachexia candidate genes. This
may indicate that the genetic aetiology of longitudinal BMI
is different than cross-sectional BMI; however, larger sample
sizes will be required to clarify this issue. The current report
begins to ﬁll the void of reported GWASes investigating
cachexia-related traits and provides a foundation for
expanding this work to larger case populations with more ex-
tensive phenotyping for monitoring cachexia.
In the current report, we took advantage of a publicly avail-
able dataset to test the hypothesis that a shared genetic
aetiology exists for ΔBMI among cancer and COPD cases.
We considered SNPs with P< 5 × 108, the generally accepted
threshold for statistical signiﬁcance in GWAS, as statistically
signiﬁcant because it has been shown to account both for
the number of variants tested and the LD structure of the ge-
nome.19,20 Further, the Bonferroni adjusted threshold for
418 365 SNPs tested in four GWASes is α = 3.0 × 108, and
the ﬁnding with DOCK1 among GI cancer cases is also below
this more conservative level of statistical signiﬁcance
(P = 1.9 × 108). We do acknowledge that the sample sizes be-
came relatively small when we examined individual groups of
cancer patients. Despite this limitation, the rs4751240 ﬁnding
in DOCK1 did reach a level of genome-wide signiﬁcance
among GI cancer cases, and we were able to replicate the ﬁnd-
ing among COPD cases contributing to a meta-analysis of
P = 9.3 × 1010. This ﬁnding supports the hypothesis that a
shared genetic aetiology exists for ΔBMI among GI cancer
and COPD cases and also underscores the need for further
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investigations into larger cancer and COPD populations to in-
crease the power to detect additional signals. Further, our in-
vestigation was underpowered for additional genetic analyses
such as epistasis. In future investigations, we plan to investi-
gate the role of epistasis in cachexia by, for example, testing
for signiﬁcant genetic interactions between the DOCK1 SNP
identiﬁed in the current analyses and variants in other candi-
date genes whose role in cachexia has been implicated.
Further limitations of the analyses include an inability to
address the temporal relationship between disease diagnoses
and ΔBMI in our analyses. It is possible, for example, that an
individual received a cancer diagnosis many years before the
initial BMI time point used to generate the ΔBMI phenotype
in FHS. We performed our analyses in a longitudinal,
population-based cohort and screened for participants over
the age of 40 and only considered the last three consecutive
BMI measurements reported among cancer and COPD cases.
The median age for the ﬁrst BMI measurement included in
the GI cancer analysis was 69 with a median follow-up period
of 7 years (Table 1). With the focus on the last three consec-
utive time points with BMI data available in FHS combined
with the advanced age of the population under investigation,
the majority of cancer diagnoses would most likely have been
made either prior or during the window we investigated
ΔBMI. Although timing of diagnosis of cancer relative to
ΔBMI is important, even more important issues are the stage,
extent, and treatment of the cancer, including consideration
of course of chemotherapy and any resultant toxicity, relative
to ΔBMI. We plan to pursue these more detailed character-
izations in future studies. Cancers are likely present for years
before diagnoses are made, and the pre-diagnosis duration is
typically unknown. We think that the fact that we have found
interesting genetic association results with these limitations
argues that there are likely important signals to ﬁnd.
The current report has many limitations. We mined a pub-
lically available study, the FHS, to investigate ΔBMI among
COPD and cancer cases. The FHS participants had BMI mea-
sured every 2–4 years. The ideal study design would ascertain
patients for longitudinal assessments of cachexia, including
measuring BMI and/or more precise measurements of mus-
cle mass every 3–6months in addition to other characteristics
established in the cachexia consensus deﬁnition.8 Further,
our sample sizes became small when we restricted analyses
to cancer and COPD subsets of the population. As we used
a hypothesis-free approach to search for genetic variants as-
sociated with ΔBMI among cancer and COPD cases, replicat-
ing the ﬁnding in independent populations ascertained for
cachexia will be a crucial next step.
The current analysis demonstrates evidence for the in-
volvement of the DOCK1 gene with ΔBMI among both GI can-
cer and COPD cases. The current investigation has highlighted
genes known for their involvement in energy metabolism and
muscle maintenance as associated with ΔBMI. Future direc-
tions will include collection and analysis of gene expression
data to identify expression biomarkers associated with ΔBMI
among COPD and cancer cases in addition to more informa-
tion on cancer diagnosis, stage, extent, and treatment. Our
future efforts will be directed at analysing additional longitu-
dinal data characterizing both genetic and gene expression to
gain further insight on biomarkers that can be used to moni-
tor the development and prognosis of cachexia.
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